Disorders of high-density lipoprotein biogenesis

Larbi Krimbou, Isabelle Ruel, Zari Dastani, Khalid Alrasadi, Houssein Hajj Hassan, Iulia Iatan, Michel Marcil, Jacques Genest

Research output: Contribution to journalArticle

Abstract

The characterization of the atheroprotective role of high-density lipoproteins (HDL) made in the past two decades has rekindled interest in modulating HDL for therapeutic purposes. Rare deficiencies of HDL have allowed the identification of specific proteins acting as structural moieties, enzymes, lipid transfer proteins, cellular lipid transporters, and ligands for cellular receptors; these, in turn, represent potential drug targets. The study of several of these HDL deficiency states has shown the importance of cellular cholesterol transport in HDL metabolism. Based on a better understanding of the physiology of HDL formation, many cases of severe HDL deficiency in man can now be explained at the cellular level. Disorders of HDL biogenesis in man - apolipoprotein (apo) AI defects, mutations at the adenosine triphosphate (ATP) binding cassette AI (ABCA1), defects of specific lipases that modulate HDL, such as sphingomyelinase, the HDL deficiency seen in Niemann-Pick disease type C (NPC) - can be linked to abnormal formation of nascent HDL particles via the ABCA1 transporter. Deficiency in lecithin:cholesterol acyl transferase impedes the formation of mature HDL particles, once nascent HDL particles are formed. As a consequence, modulating cellular cholesterol efflux and apo AI secretion - and thereby nascent HDL particles - may be an appealing strategy to raise HDL for therapeutic purposes.

Original languageEnglish
Pages (from-to)39-47
Number of pages9
JournalAnnals of Medicine
Volume40
Issue numberSUPPL. 1
DOIs
Publication statusPublished - Feb 2008

Fingerprint

HDL Lipoproteins
Apolipoprotein A-I
Cholesterol
Type C Niemann-Pick Disease
Sphingomyelin Phosphodiesterase
Lecithins
Transferases
Lipase
Adenosine Triphosphate
Ligands
Lipids
Mutation
Familial HDL deficiency

Keywords

  • Genetics
  • High-density lipoproteins
  • Lipoproteins
  • Prevention

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Krimbou, L., Ruel, I., Dastani, Z., Alrasadi, K., Hassan, H. H., Iatan, I., ... Genest, J. (2008). Disorders of high-density lipoprotein biogenesis. Annals of Medicine, 40(SUPPL. 1), 39-47. https://doi.org/10.1080/07853890701689637

Disorders of high-density lipoprotein biogenesis. / Krimbou, Larbi; Ruel, Isabelle; Dastani, Zari; Alrasadi, Khalid; Hassan, Houssein Hajj; Iatan, Iulia; Marcil, Michel; Genest, Jacques.

In: Annals of Medicine, Vol. 40, No. SUPPL. 1, 02.2008, p. 39-47.

Research output: Contribution to journalArticle

Krimbou, L, Ruel, I, Dastani, Z, Alrasadi, K, Hassan, HH, Iatan, I, Marcil, M & Genest, J 2008, 'Disorders of high-density lipoprotein biogenesis', Annals of Medicine, vol. 40, no. SUPPL. 1, pp. 39-47. https://doi.org/10.1080/07853890701689637
Krimbou L, Ruel I, Dastani Z, Alrasadi K, Hassan HH, Iatan I et al. Disorders of high-density lipoprotein biogenesis. Annals of Medicine. 2008 Feb;40(SUPPL. 1):39-47. https://doi.org/10.1080/07853890701689637
Krimbou, Larbi ; Ruel, Isabelle ; Dastani, Zari ; Alrasadi, Khalid ; Hassan, Houssein Hajj ; Iatan, Iulia ; Marcil, Michel ; Genest, Jacques. / Disorders of high-density lipoprotein biogenesis. In: Annals of Medicine. 2008 ; Vol. 40, No. SUPPL. 1. pp. 39-47.
@article{39cce2430cad4d3f8306affeaea2f1e0,
title = "Disorders of high-density lipoprotein biogenesis",
abstract = "The characterization of the atheroprotective role of high-density lipoproteins (HDL) made in the past two decades has rekindled interest in modulating HDL for therapeutic purposes. Rare deficiencies of HDL have allowed the identification of specific proteins acting as structural moieties, enzymes, lipid transfer proteins, cellular lipid transporters, and ligands for cellular receptors; these, in turn, represent potential drug targets. The study of several of these HDL deficiency states has shown the importance of cellular cholesterol transport in HDL metabolism. Based on a better understanding of the physiology of HDL formation, many cases of severe HDL deficiency in man can now be explained at the cellular level. Disorders of HDL biogenesis in man - apolipoprotein (apo) AI defects, mutations at the adenosine triphosphate (ATP) binding cassette AI (ABCA1), defects of specific lipases that modulate HDL, such as sphingomyelinase, the HDL deficiency seen in Niemann-Pick disease type C (NPC) - can be linked to abnormal formation of nascent HDL particles via the ABCA1 transporter. Deficiency in lecithin:cholesterol acyl transferase impedes the formation of mature HDL particles, once nascent HDL particles are formed. As a consequence, modulating cellular cholesterol efflux and apo AI secretion - and thereby nascent HDL particles - may be an appealing strategy to raise HDL for therapeutic purposes.",
keywords = "Genetics, High-density lipoproteins, Lipoproteins, Prevention",
author = "Larbi Krimbou and Isabelle Ruel and Zari Dastani and Khalid Alrasadi and Hassan, {Houssein Hajj} and Iulia Iatan and Michel Marcil and Jacques Genest",
year = "2008",
month = "2",
doi = "10.1080/07853890701689637",
language = "English",
volume = "40",
pages = "39--47",
journal = "Annals of Medicine",
issn = "0785-3890",
publisher = "Informa Healthcare",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Disorders of high-density lipoprotein biogenesis

AU - Krimbou, Larbi

AU - Ruel, Isabelle

AU - Dastani, Zari

AU - Alrasadi, Khalid

AU - Hassan, Houssein Hajj

AU - Iatan, Iulia

AU - Marcil, Michel

AU - Genest, Jacques

PY - 2008/2

Y1 - 2008/2

N2 - The characterization of the atheroprotective role of high-density lipoproteins (HDL) made in the past two decades has rekindled interest in modulating HDL for therapeutic purposes. Rare deficiencies of HDL have allowed the identification of specific proteins acting as structural moieties, enzymes, lipid transfer proteins, cellular lipid transporters, and ligands for cellular receptors; these, in turn, represent potential drug targets. The study of several of these HDL deficiency states has shown the importance of cellular cholesterol transport in HDL metabolism. Based on a better understanding of the physiology of HDL formation, many cases of severe HDL deficiency in man can now be explained at the cellular level. Disorders of HDL biogenesis in man - apolipoprotein (apo) AI defects, mutations at the adenosine triphosphate (ATP) binding cassette AI (ABCA1), defects of specific lipases that modulate HDL, such as sphingomyelinase, the HDL deficiency seen in Niemann-Pick disease type C (NPC) - can be linked to abnormal formation of nascent HDL particles via the ABCA1 transporter. Deficiency in lecithin:cholesterol acyl transferase impedes the formation of mature HDL particles, once nascent HDL particles are formed. As a consequence, modulating cellular cholesterol efflux and apo AI secretion - and thereby nascent HDL particles - may be an appealing strategy to raise HDL for therapeutic purposes.

AB - The characterization of the atheroprotective role of high-density lipoproteins (HDL) made in the past two decades has rekindled interest in modulating HDL for therapeutic purposes. Rare deficiencies of HDL have allowed the identification of specific proteins acting as structural moieties, enzymes, lipid transfer proteins, cellular lipid transporters, and ligands for cellular receptors; these, in turn, represent potential drug targets. The study of several of these HDL deficiency states has shown the importance of cellular cholesterol transport in HDL metabolism. Based on a better understanding of the physiology of HDL formation, many cases of severe HDL deficiency in man can now be explained at the cellular level. Disorders of HDL biogenesis in man - apolipoprotein (apo) AI defects, mutations at the adenosine triphosphate (ATP) binding cassette AI (ABCA1), defects of specific lipases that modulate HDL, such as sphingomyelinase, the HDL deficiency seen in Niemann-Pick disease type C (NPC) - can be linked to abnormal formation of nascent HDL particles via the ABCA1 transporter. Deficiency in lecithin:cholesterol acyl transferase impedes the formation of mature HDL particles, once nascent HDL particles are formed. As a consequence, modulating cellular cholesterol efflux and apo AI secretion - and thereby nascent HDL particles - may be an appealing strategy to raise HDL for therapeutic purposes.

KW - Genetics

KW - High-density lipoproteins

KW - Lipoproteins

KW - Prevention

UR - http://www.scopus.com/inward/record.url?scp=38849186016&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38849186016&partnerID=8YFLogxK

U2 - 10.1080/07853890701689637

DO - 10.1080/07853890701689637

M3 - Article

VL - 40

SP - 39

EP - 47

JO - Annals of Medicine

JF - Annals of Medicine

SN - 0785-3890

IS - SUPPL. 1

ER -